Dissecting cancer pathways and vulnerabilities with RNAi

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 70, Issue , 2005, Pages 435-444

  Westbrook, T F ^a   Stegmeier, F ^a   Elledge, S J ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENETICS; CANCER SCREENING; CLINICAL PATHWAY; CONFERENCE PAPER; DISSECTION; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; HUMAN; HUMAN GENOME; MAMMAL CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; EPIGENETICS; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY;

ANIMALS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; GENOMICS; HUMANS; NEOPLASMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

INVERTEBRATA; MAMMALIA;

MICRORNA 30; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS VECTOR;

EID: 33746419566     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2005.70.031     Document Type: Conference Paper

References (95)

1. Ashkenazi A. and Dixit V.M. 1999. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11: 255.
2. Ashrafi K., Chang F.Y., Watts J.L., Fraser A.G., Kamath R.S., Ahringer J., and Ruvkun G. 2003. Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature 421: 268.
3. Aza-Blanc P., Cooper C.L., Wagner K., Batalov S., Deveraux Q.L., and Cooke M.P. 2003. Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol. Cell 12: 627.
4. Baeg G.H., Zhou R., and Perrimon N. 2005. Genome-wide RNAi analysis of JAK/STAT signaling components in Drosophila. Genes Dev. 19: 1861.
5. Berns K., Hijmans E.M., Mullenders J., Brummelkamp T.R., Velds A., Heimerikx M., Kerkhoven R.M., Madiredjo M., Nijkamp W., Weigelt B., Agami R., Ge W., Cavet G., Linsley P.S., Beijersbergen R.L., and Bernards R. 2004. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428: 431.
6. Bernstein E., Caudy A.A., Hammond S.M., and Hannon G.J. 2001. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409: 363.
7. Boutros M., Kiger A.A., Armknecht S., Kerr K., Hild M., Koch B., Haas S.A., Consortium H.F., Paro R., and Perrimon N. 2004. Genome-wide RNAi analysis of growth and viability in Drosophila cells. Science 303: 832.
8. Brummelkamp T.R. and Bernards R. 2003. New tools for functional mammalian cancer genetics. Nat. Rev. Cancer 3: 781.
9. Brummelkamp T.R., Bernards R., and Agami R. 2002. A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550.
10. Brummelkamp T.R., Nijman S.M., Dirac A.M., and Bernards R. 2003. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424: 797.
11. Cai X., Hagedorn C.H., and Cullen B.R. 2004. Human micro RNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 10: 1957.
12. Chambers A.F., Groom A.C., and MacDonald I.C. 2002. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2: 563.
13. Chong J.A., Tapia-Ramirez J., Kim S., Toledo-Aral J.J., Zheng Y., Boutros M.C., Altshuller Y.M., Frohman M.A., Kraner S.D., and Mandel G. 1995. REST: A mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell 80: 949.
14. Clark E.A., Golub T.R., Lander E.S., and Hynes R.O. 2000. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406: 532.
15. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., Cross N.C., Tefferi A., Malone J., Alam R., Schrier S.L., Schmid J., Rose M., Vandenberghe P., Verhoef G., Boogaerts M., Wlodarska I., Kantarjian H., Marynen P., Coutre S.E., Stone R., and Gilliland D.G. 2003. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348: 1201.
16. Cullen B.R. 2004. Transcription and processing of human microRNA precursors. Mol. Cell 16: 861.
17. D'Andrea A. 2003. Fanconi anemia. Curr. Biol. 13: R546.
18. DasGupta R., Kaykas A., Moon R.T., and Perrimon N. 2005. Functional genomic analysis of the Wnt-wingless signaling pathway. Science 308: 826.
19. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B.J., Corless C., Fletcher C.D., and Joensuu H. 2002. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347: 472.
20. Dickins R.A., Hemann M.T., Zilfou J.T., Simpson D.R., Ibarra I., Hannon G.J., and Lowe S.W. 2005. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 37: 1289.
21. Dolma S., Lessnick S.L., Hahn W.C., and Stockwell B.R. 2003. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3: 285.
22. Douma S., Van Laar T., Zevenhoven J., Meuwissen R., Van Garderen E., and Peeper D.S. 2004. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430: 1034.
23. Druker B.J. 2002. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol. Med. 8: S14.
24. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., and Lydon N.B. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2: 561.
25. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., and Sawyers C.L. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344: 1031.
26. Dykxhoorn D.M., Novina C.D., and Sharp P.A. 2003. Killing the messenger: Short RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol. 4: 457.
27. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494.
28. Fantin V.R., Berardi M.J., Scorrano L., Korsmeyer S.J., and Leder P. 2002. A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell 2: 29.
29. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M., Jackson S.P., Smith G.C., and Ashworth A. 2005. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917.
30. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., and Mello C.C. 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806.
31. Giaever G., Chu A.M., Ni L., Connelly C., Riles L., Veronneau S., Dow S., Lucau-Danila A., Anderson K., Andre B., Arkin A.P., Astromoff A., El-Bakkoury M., Bangham R., Benito R., Brachat S., Campanaro S., Curtiss M., Davis K., Deutschbauer A., Entian K.D., Flaherty P., Foury F., Garfinkel D.J., and Gerstein M., et al. 2002. Functional profiling of the Saccharomyces cerevisiae genome. Nature 418: 387.
32. Goldfarb M., Shimizu K., Perucho M., and Wigler M. 1982. Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature 296: 404.
33. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., and Sawyers C.L. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876.
34. Grishok A., Pasquinelli A.E., Conte D., Li N., Parrish S., Ha I., Baillie D.L., Fire A., Ruvkun G., and Mello C.C. 2001. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell 106: 23.
35. Guarente L. 1993. Synthetic enhancement in gene interaction: A genetic tool come of age. Trends Genet. 9: 362.
36. Hamilton B., Dong Y., Shindo M., Liu W., Odell I., Ruvkun G., and Lee S.S. 2005. A systematic RNAi screen for longevity genes in C. elegans. Genes Dev. 19: 1544.
37. Hanahan D. and Weinberg R.A. 2000. The hallmarks of cancer. Cell 100: 57.
38. Hannon G.J. 2002. RNA interference. Nature 418: 244.
39. Hannon G.J. and Rossi J.J. 2004. Unlocking the potential of the human genome with RNA interference. Nature 431: 371.
40. Hensel M., Shea J.E., Gleeson C., Jones M.D., Dalton E., and Holden D.W. 1995. Simultaneous identification of bacterial virulence genes by negative selection. Science 269: 400.
41. Hutvagner G., McLachlan J., Pasquinelli A.E., Balint E., Tuschl T., and Zamore P.D. 2001. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 293: 834.
42. Jonkers J. and Berns A. 2002. Conditional mouse models of sporadic cancer. Nat. Rev. Cancer 2: 251.
43. _. 2004. Oncogene addiction: Sometimes a temporary slavery. Cancer Cell 6: 535.
44. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., Guise T.A., and Massague J. 2003. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537.
45. Ketting R.F., Fischer S.E., Bernstein E., Sijen T., Hannon G.J., and Plasterk R.H. 2001. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 15: 2654.
46. Kittler R., Putz G., Pelletier L., Poser I., Heninger A.K., Drechsel D., Fischer S., Konstantinova I., Habermann B., Grabner H., Yaspo M.L., Himmelbauer H., Korn B., Neugebauer K., Pisabarro M.T., and Buchholz F. 2004. An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. Nature 432: 1036.
47. Lee S.S., Lee R.Y., Fraser A.G., Kamath R.S., Ahringer J., and Ruvkun G. 2003. A systematic RNAi screen identifies a critical role for mitochondria in C. elegans longevity. Nat. Genet. 33: 40.
48. Lin S.Y. and Elledge S.J. 2003. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113: 881.
49. Logan C.Y. and Nusse R. 2004. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 20: 781.
50. Lum L., Yao S., Mozer B., Rovescalli A., Von Kessler D., Nirenberg M., and Beachy P.A. 2003. Identification of Hedgehog pathway components by RNAi in Drosophila cultured cells. Science 299: 2039.
51. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350: 2129.
52. MacKeigan J.P., Murphy L.O., and Blenis J. 2005. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat. Cell Biol. 7: 591.
53. Malphettes L. and Fussenegger M. 2004. Macrolide- and tetracycline-adjustable siRNA-mediated gene silencing in mammalian cells using polymerase II-dependent promoter derivatives. Biotechnol. Bioeng. 88: 417.
54. Manche L., Green S.R., Schmedt C., and Mathews M.B. 1992. Interactions between double-stranded RNA regulators and the protein kinase DAI. Mol. Cell. Biol. 12: 5238.
55. Meetei A.R., de Winter J.P., Medhurst A.L., Wallisch M., Waisfisz Q., van de Vrugt H.J., Oostra A.B., Yan Z., Ling C., Bishop C.E., Hoatlin M.E., Joenje H., and Wang W. 2003. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat. Genet. 35: 165.
56. Meister G. and Tuschl T. 2004. Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343.
57. Minks M.A., West D.K., Benvin S., and Baglioni C. 1979. Structural requirements of double-stranded RNA for the activation of 2′,5′- oligo(A) polymerase and protein kinase of interferon-treated HeLa cells. J. Biol. Chem. 254: 10180.
58. Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W., Giri D.D., Viale A., Olshen A.B., Gerald W.L., and Massague J. 2005. Genes that mediate breast cancer metastasis to lung. Nature 436: 518.
59. Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J.J., Wu H., and Sawyers C.L. 2001. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. 98: 10314.
60. Nijman S.M., Huang T.T., Dirac A.M., Brummelkamp T.R., Kerkhoven R.M., D'Andrea A.D., and Bernards R. 2005. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol. Cell 17: 331.
61. Nybakken K. and Perrimon N. 2002. Hedgehog signal transduction: Recent findings. Curr. Opin. Genet. Dev. 12: 503.
62. Paddison P.J. and Hannon G.J. 2002. RNA interference: The new somatic cell genetics? Cancer Cell 2: 17.
63. Paddison P.J., Caudy A.A., Bernstein E., Hannon G.J., and Conklin DS. 2002. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 16: 948.
64. Paddison P.J., Silva J.M., Conklin D.S., Schlabach M., Li M., Aruleba S., Balija V., O'Shaughnessy A., Gnoj L., Scobie K., Chang K., Westbrook T., Cleary M., Sachidanandam R., McCombie W.R., Elledge S.J., and Hannon G.J. 2004. A resource for large-scale RNA-interference-based screens in mammals. Nature 428: 427.
65. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M. 2004. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497.
66. Peeper D.S., Shvarts A., Brummelkamp T., Douma S., Koh E.Y., Daley G.Q., and Bernards R. 2002. A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nat. Cell Biol. 4: 148.
67. Schoenherr C.J. and Anderson D.J. 1995. The neuron-restrictive silencer factor (NRSF): A coordinate repressor of multiple neuron-specific genes. Science 267: 1360.
68. Shih C. and Weinberg R.A. 1982. Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 29: 161.
69. Shoemaker D.D., Lashkari D.A., Morris D., Mittmann M., and Davis R.W. 1996. Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy. Nat. Genet. 14: 450.
70. Shvarts A., Brummelkamp T.R., Scheeren F., Koh E., Daley G.Q., Spits H., and Bernards R. 2002. A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling. Genes Dev. 16: 681.
71. Sieburth D., Ch'ng Q., Dybbs M., Tavazoie M., Kennedy S., Wang D., Dupuy D., Rual J.F., Hill D.E., Vidal M., Ruvkun G., and Kaplan J.M. 2005. Systematic analysis of genes required for synapse structure and function. Nature 436: 510.
72. Siegel P.M. and Massague J. 2003. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat. Rev. Cancer 3: 807.
73. Silva J., Chang K., Hannon G.J., and Rivas F.V. 2004. RNA-interference-based functional genomics in mammalian cells: Reverse genetics coming of age. Oncogene 23: 8401.
74. Silva J.M., Li M.Z., Chang K., Ge W., Golding M.C., Rickles R.J., Siolas D., Hu G., Paddison P.J., Schlabach M.R., Sheth N., Bradshaw J., Burchard J., Kulkarni A., Cavet G., Sachidanandam R., McCombie W.R., Cleary M.A., Elledge S.J., and Hannon G.J. 2005. Second-generation shRNA libraries covering the mouse and human genomes. Nat. Genet. 37: 1281.
75. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., and Ullrich A., et al. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707.
76. Sordella R., Bell D.W., Haber D.A., and Settleman J. 2004. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163.
77. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. 1998. How cells respond to interferons. Annu. Rev. Biochem. 67: 227.
78. Stegmeier F., Hu G., Rickles R.J., Hannon G.J., and Elledge S.J. 2005. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc. Natl. Acad. Sci. 102: 13212.
79. Sui G., Soohoo C., Affar el B., Gay F., Shi Y., and Forrester W.C. 2002. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. 99: 5515.
80. Tiscornia G., Tergaonkar V., Galimi F., and Verma I.M. 2004. CRE recombinase-inducible RNA interference mediated by lentiviral vectors. Proc. Natl. Acad. Sci. 101: 7347.
81. Torrance C.J., Agrawal V., Vogelstein B., and Kinzler K.W. 2001. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat. Biotechnol. 19: 940.
82. Tuveson D.A., Willis N.A., Jacks T., Griffin J.D., Singer S., Fletcher C.D., Fletcher J.A., and Demetri G.D. 2001. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications. Oncogene 20: 5054.
83. Ventura A., Meissner A., Dillon C.P., McManus M., Sharp P.A., Van Parijs L., Jaenisch R., and Jacks T. 2004. Cre-lox-regulated conditional RNA interference from transgenes. Proc. Natl. Acad. Sci. 101: 10380.
84. Vivanco I. and Sawyers C.L. 2002. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2: 489.
85. Wang Y., Engels I.H., Knee D.A., Nasoff M., Deveraux Q.L., and Quon K.C. 2004. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 5: 501.
86. Weinstein I.B. 2002. Cancer. Addiction to oncogenes: The Achilles heal of cancer. Science 297: 63.
87. Westbrook T.F., Martin E.S., Schlabach M.R., Leng Y., Liang A.C., Feng B., Zhao J.J., Roberts T.M., Mandel G., Hannon G.J., Depinho R.A., Chin L., and Elledge S.J. 2005. A genetic screen for candidate tumor suppressors identifies REST. Cell 121: 837.
88. Willingham A.T., Deveraux Q.L., Hampton G.M., and AzaBlanc P. 2004. RNAi and HTS: Exploring cancer by systematic loss-of-function. Oncogene 23: 8392.
89. Winzeler E.A., Shoemaker D.D., Astromoff A., Liang H., Anderson K., Andre B., Bangham R., Benito R., Boeke J.D., Bussey H., Chu A.M., Connelly C., Davis K., Dietrich F., Dow S.W., El Bakkoury M., Foury F., Friend S.H., Gentalen E., Giaever G., Hegemann J.H., Jones T., Laub M., Liao H., and R.W. Davis, et al. 1999. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 285: 901.
90. Wiznerowicz M. and Trono D. 2003. Conditional suppression of cellular genes: Lentivirus vector-mediated drug-inducible RNA interference. J. Virol. 77: 8957.
91. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., Savagner P., Gitelman I., Richardson A., and Weinberg RA. 2004. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927.
92. Yu J.Y., DeRuiter S.L., and Turner D.L. 2002. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc. Natl. Acad. Sci. 99: 6047.
93. Zeng Y., Wagner E.J., and Cullen B.R. 2002. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol. Cell 9: 1327.
94. Zheng L., Liu J., Batalov S., Zhou D., Orth A., Ding S., and Schultz P.G. 2004. An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc. Natl. Acad. Sci. 101: 135.
95. Zhou H., Xia X.G., and Xu Z. 2005. An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi. Nucleic Acids Res. 33: e62.